News
MRNA
200.10
-1.25%
-2.53
Is Vaccine Data Leak Altering The Investment Case For Moderna Stock?
Simply Wall St · 16h ago
Moderna: Why Positive Phase 3 Results Weren't Enough
Seeking Alpha · 18h ago
Moderna Investors Should Brace for More Whiplash -- Heard on the Street
The Wall Street Journal · 1d ago
Moderna's Cancer Vaccine Success Doesn't Live Up to Early Hype
The Wall Street Journal · 1d ago
Tech stocks weigh on Nasdaq for second week; Roper leads gainers
Seeking Alpha · 1d ago
Moderna’s Cancer Vaccine Earns Praise from Doctors amid Stock Selloff
TipRanks · 1d ago
Moderna Executives Sold Shares in Trades Planned Before Vaccine Results
The Wall Street Journal · 1d ago
Moderna: Data Leak Brings Us No Closer To Truth About Cancer Vaccine
Seeking Alpha · 1d ago
The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
MarketWatch · 1d ago
Merck/Moderna's Melanoma Combination Therapy Delivers Promising Phase 3 Trial Results
Seeking Alpha · 1d ago
Moderna, Meta, SpaceX, Bloom Energy, AT&T, and More Stocks That Explain Today's Market
Barron‘s · 1d ago
Moderna’s Norovirus Vaccine Trial Reaches Key Milestone, Supporting Its Post-COVID Growth Story
TipRanks · 1d ago
Analysts weigh in on Moderna's big drop following cancer vaccine results
Seeking Alpha · 1d ago
Nasdaq 100 Movers: MRNA, HONIV
NASDAQ · 1d ago
Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win
NASDAQ · 1d ago
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?
The Motley Fool · 1d ago
Moderna's Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure
Barron‘s · 1d ago
Unusually active option classes on open October 23rd
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Inventiva (IVA) and Quest Diagnostics (DGX)
TipRanks · 2d ago
Moderna Stock Slides Again Friday: What's Going On?
Benzinga · 2d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).